易瑞生物
(300942)
| 流通市值：31.96亿 | | | 总市值：31.96亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 412,014,778.36 | 392,838,438.45 | 449,803,934.39 | 397,216,726.53 |
| 交易性金融资产 | 187,642,545.12 | 235,295,655.31 | 145,046,268.56 | 139,506,128.75 |
| 衍生金融资产 | - | - | 771,150.84 | 1,198,329.56 |
| 应收票据及应收账款 | 102,742,507.13 | 111,334,198 | 100,412,073.93 | 90,149,457.06 |
| 其中：应收票据 | 944,187 | 1,123,897.96 | 681,861.96 | 220,936 |
| 应收账款 | 101,798,320.13 | 110,210,300.04 | 99,730,211.97 | 89,928,521.06 |
| 预付款项 | 16,367,827.91 | 9,100,142.13 | 4,769,315.8 | 5,466,489.87 |
| 其他应收款合计 | 5,115,807.55 | 4,402,768.48 | 4,129,538.63 | 5,195,502.84 |
| 存货 | 62,276,117.18 | 54,774,024.42 | 57,910,460.72 | 52,711,532.65 |
| 其他流动资产 | 12,095,642.18 | 10,069,023.36 | 12,530,986.09 | 10,784,236.56 |
| 流动资产合计 | 798,255,225.43 | 817,814,250.15 | 775,373,728.96 | 702,228,403.82 |
| 非流动资产: | | | | |
| 长期股权投资 | 64,915,967.23 | 78,520,051.4 | 84,480,660.5 | 96,970,169.15 |
| 其他权益工具投资 | 5,000,000 | 5,000,000 | - | - |
| 固定资产 | 569,785,559.5 | 576,012,583.37 | 570,435,095.39 | 501,684,913.54 |
| 在建工程 | 2,261,746.78 | 2,261,746.78 | 6,805,858.89 | 70,901,095.38 |
| 无形资产 | 36,864,931.91 | 37,351,464.8 | 37,787,164.35 | 38,272,447.23 |
| 长期待摊费用 | 1,135,380.29 | 541,072.59 | 2,803,768.73 | 1,722,757.31 |
| 递延所得税资产 | 9,743,309.32 | 7,046,695.5 | 2,901,758.03 | 1,324,627.17 |
| 其他非流动资产 | - | - | 972,000 | 7,049,966.93 |
| 非流动资产合计 | 689,706,895.03 | 706,733,614.44 | 706,186,305.89 | 717,925,976.71 |
| 资产总计 | 1,487,962,120.46 | 1,524,547,864.59 | 1,481,560,034.85 | 1,420,154,380.53 |
| 流动负债: | | | | |
| 短期借款 | 11,000,000 | 21,000,000 | - | - |
| 衍生金融负债 | - | - | - | 0 |
| 应付票据及应付账款 | 44,768,316.48 | 72,955,132.11 | 74,837,634.92 | 57,880,217.3 |
| 应付账款 | 44,768,316.48 | 72,955,132.11 | 74,837,634.92 | 57,880,217.3 |
| 预收款项 | 413,841.8 | 68,606.34 | 431,047.48 | 693,052.66 |
| 合同负债 | 14,180,324.77 | 17,182,705.33 | 16,860,113.84 | 17,312,180.03 |
| 应付职工薪酬 | 15,606,385.31 | 21,589,845.65 | 17,618,216.62 | 16,514,048.27 |
| 应交税费 | 3,716,156.51 | 5,597,456.67 | 1,437,542.2 | 717,107.11 |
| 其他应付款合计 | 3,947,732.77 | 6,687,912.29 | 5,099,993 | 3,496,126.68 |
| 一年内到期的非流动负债 | 13,981,966.39 | 13,551,694.17 | 31,991,821.43 | 11,026,204.1 |
| 其他流动负债 | 1,843,442.23 | 2,070,000.03 | 2,027,909.98 | 1,836,564.83 |
| 流动负债合计 | 109,458,166.26 | 160,703,352.59 | 150,304,279.47 | 109,475,500.98 |
| 非流动负债: | | | | |
| 长期借款 | 174,515,115.11 | 155,966,607.22 | 160,533,880.61 | 163,941,237.36 |
| 应付债券 | 261,990,170.23 | 257,029,652.59 | 251,959,949.58 | 273,805,895.29 |
| 预计负债 | 2,080,000 | 2,080,000 | 2,080,000 | 2,080,000 |
| 递延收益 | 40,496,794.82 | 41,087,770.33 | 6,330,243.9 | 5,431,446.3 |
| 非流动负债合计 | 479,082,080.16 | 456,164,030.14 | 420,904,074.09 | 445,258,578.95 |
| 负债合计 | 588,540,246.42 | 616,867,382.73 | 571,208,353.56 | 554,734,079.93 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 405,068,876 | 405,068,764 | 405,068,607 | 401,317,665 |
| 其他权益工具 | 61,452,801.52 | 61,452,987.54 | 62,380,255.73 | 68,386,086.89 |
| 资本公积 | 221,583,389.31 | 221,564,679.31 | 220,636,393.34 | 190,223,361.02 |
| 其他综合收益 | -113,455.01 | 104,358.53 | -164,030.37 | -19,980.33 |
| 盈余公积 | 55,652,955.25 | 55,652,955.25 | 55,512,481.54 | 55,512,481.54 |
| 未分配利润 | 149,976,995.45 | 160,236,481.67 | 164,656,669.77 | 148,973,123.19 |
| 归属于母公司股东权益合计 | 893,621,562.52 | 904,080,226.3 | 908,090,377.01 | 864,392,737.31 |
| 少数股东权益 | 5,800,311.52 | 3,600,255.56 | 2,261,304.28 | 1,027,563.29 |
| 股东权益合计 | 899,421,874.04 | 907,680,481.86 | 910,351,681.29 | 865,420,300.6 |
| 负债和股东权益合计 | 1,487,962,120.46 | 1,524,547,864.59 | 1,481,560,034.85 | 1,420,154,380.53 |
| 公告日期 | 2026-04-27 | 2026-04-27 | 2025-10-28 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |